Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
Clinical trial NCT04251533 · TERMINATED
Trial details
- NCT number
- NCT04251533
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-08
- Primary completion
- 2023-05-31
- Enrollment
- 137
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.